Azacytidine (AZA), which is a representative drug in DNMT inhibitors, has been shown to elevate the expression of tumor antigens and immune co-stimulatory molecules, leading to enhanced antigen presentation and increased cytotoxicity of effector T cells [56]. This evidence concerns the gene DNMT1 and neoplasm.